First Surgeries Using Stryker’s Infinity With Adaptis and Everlast Successfully Completed in Europe
Infinity with Adaptis and Everlast Total Ankle System, featuring Prophecy Surgical Planning, is designed to deliver efficient and accurate implementation AMSTERDAM–(BUSINESS... Read more.
Faraday Future Issues Statement on Recent Social Media Post
LOS ANGELES–(BUSINESS WIRE)–Faraday Future Intelligent Electric Inc. (“Faraday Future” or the “Company”) (NASDAQ: FFIE), a California-based global... Read more.
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
A breakthrough approach and supporting data using epigenome editing technology for the treatment of a type of muscular dystrophy, LAMA2-congenital muscular dystrophy... Read more.
4me Announces Global User Event ‘Connect 24’ – Showcasing Innovations in Service Management
SANTA BARBARA, Calif.–(BUSINESS WIRE)–4me®, the SaaS-based Service Management software platform for the modern enterprise, announces its 9th annual... Read more.
UMC Reports Sales for April 2024
TAIPEI, Taiwan–(BUSINESS WIRE)–United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC”), today reported unaudited net sales for the month... Read more.
KKR and Marriott International to Launch Midscale Hospitality Segment in Japan with Four Points Express by Sheraton
Conversion of 14 hotels marks Marriott International’s debut of affordable midscale segment in Asia Pacific TOKYO–(BUSINESS WIRE)–KKR, a leading global... Read more.
Kosmos Energy Announces First Quarter 2024 Results
DALLAS–(BUSINESS WIRE)–Kosmos Energy Ltd. (“Kosmos” or the “Company”) (NYSE/LSE: KOS) announced today its financial and operating results for... Read more.
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced... Read more.
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
Galderma has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe... Read more.
ADTRAN Holdings, Inc. reports first quarter 2024 financial results
Q1 revenue above mid-point of guidance; non-GAAP profitability in line with guidance $53 million sequential improvement in GAAP operating cash flow HUNTSVILLE, Ala.–(BUSINESS... Read more.